S Fidler, Imperial College School of Medicine, London, UK
J Weber, Imperial College School of Medicine, London, UK
Published online: January 2006
DOI: 10.1038/npg.els.0005761
Human gene therapy is defined as the introduction of new genetic material into the cells of an individual with the intention of producing a therapeutic benefit for that individual. Gene therapy may be applied to any infectious disease whereby the infecting organism inserts its own genetic material into the genome of the host cell genome.
Keywords: infectious diseases; human immunodeficiency virus; gene therapy
|
Figure 1. HIV life cycle. See main text for further details.
|
|
Figure 2. Antiviral constructs for HIV gene therapy. See main text for further details.
|
|
Figure 3. Antiviral constructs: ribozymes and antisense RNA. See main text for further details.
|
|
Figure 4. Antiviral constructs: decoy RNA. See main text for further details.
|
|
Figure 5. Intracellular antibodies. See main text for further details. ER: endoplasmic reticulum.
|
|
Figure 6. Antiviral constructs: dominant negative mutants. See main text for further details.
|
| References | |
| Baenziger J, Hengartner H, Zinkernagel RM and Cole GA (1986) Induction or prevention of immunopathological disease by cloned cytotoxic T cell lines specific for lymphocytic choriomeningitis virus. European Journal of Immunology 16: 387–393. | |
| Barouch DH, Santra S, Schmitz JE, et al. (2000) Control of viraemia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486–492. | |
| Chada S, De Jesus CE, Townsend K, et al. (1993) Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes. Journal of Virology 67: 3409–3417. | |
| Cohen S, Mendelson I, Altboum Z, et al. (2000) Attenuated non-toxinogenic and non-encapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infection and Immunity 68: 4549–4558. | |
| Davis HL, McCluskie MJ, Gerin JL and Purcell RH (1996) DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proceedings of the National Academy of Sciences of the United States of America 93: 7213–7218. | |
| Greenberg P, Goodrich J and Riddell S (1991) Adoptive immunotherapy of human cytomegalovirus infection: potential role in protection from disease progression. Transplant Proceedings Supplement 23: 97–101. | |
| book Greenberg PD, Watanabe K, Gilbert M, et al. (1993) "Reconstruction of viral immunity by the adoptive transfer of T cell clones modified by gene insertion". 1993 UCLA/ACI AIDS Symposium: Gene Therapy Approaches to Treatment of HIV Infection, p. 31. | |
| Hanecak R, Brown-Driver V, Fox MC, et al. (1996) Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. Journal of Virology 70: 5203–5212. | |
| Hanke T, Blanchard TJ, Schneider J, et al. (1998) Immunogenicites of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type-1 in mice. Journal of General Virology 79: 83–90. | |
| Walker BD, Chakrabarti S, Moss B, et al. (1987) HIV specific cytotoxic T lymphocytes in seropositive individuals. Nature 328: 345–348. | |
| Further Reading | |
| Anderson WF (1992) Human gene therapy. Science 256: 808–813. | |
| Bunnell BA and Morgan RA (1998) Gene therapy for infectious diseases. Clinical Microbiology Reviews 11: 42–56. | |
| Yu M, Poeschla E and Wong-Staal F (1994) Progress towards gene therapy for HIV infection. Gene Therapy Review 1: 13–26. | |
Copyright © 2000-2013 by John Wiley & Sons, Inc., or related companies. All rights reserved.
